SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:
Corporate Presentation: Date: Monday, February 9, 2009 Time: 3:45 p.m. - 4:15 p.m. Eastern Location: Waldorf Astoria, Astor Room, New York Speaker: Graham Cooper, Chief Financial Officer Panel Discussion: Feeding the Need for New Treatments in Obesity Date: Monday, February 9, 2009 Time: 11:00 a.m. - 12:10 p.m. Eastern Location: Waldorf Astoria, East Foyer, New York Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved